Company Filing History:
Years Active: 2025
Title: Innovations of Jae-Young Um in Prostatic Hyperplasia Treatment.
Introduction
Jae-Young Um is an accomplished inventor based in Seoul, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of benign prostatic hyperplasia.
Latest Patents
Jae-Young Um holds a patent for a composition aimed at preventing or treating prostatic hyperplasia. The patent describes a pharmaceutical composition that includes mixed extracts as an effective component. This innovative composition has been shown to inhibit the expression of dihydrotestosterone, androgen receptors, prostate-specific antigens, proliferating cell nuclear antigen (PCNA), cyclin B1, and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB). Notably, it has fewer adverse side effects compared to the existing drug finasteride, making it a promising option for patients.
Career Highlights
Jae-Young Um is affiliated with the University-Industry Cooperation Group of Kyung Hee University. His work focuses on developing effective treatments that can improve patient outcomes in urology.
Collaborations
Jae-Young collaborates with Jinbong Park, who is also involved in research related to his innovative projects.
Conclusion
Jae-Young Um's contributions to the treatment of benign prostatic hyperplasia highlight the importance of innovation in pharmaceuticals. His work not only advances medical science but also offers hope for improved patient care.